ALT stock forecast
📊 Current Basics (June 2025)
| Metric | Value |
|---|---|
| Market Cap | Around $293 million (finance.yahoo.com, fullratio.com) |
| Return on Equity | About -65% (TTM) ([chartmill.com][1], [macrotrends.net]) |
| Price-to-Book | About 4× (fullratio.com, gurufocus.com) |
Altimmune is a biotech company that is now in the trial stage. Its balance sheet is robust (current ratio is around 15.8 and Altman-Z is about 18.7), but it is still losing money.
🔮 Predictions for ALT Stock
ALT stock forecast 2025
Successful Phase 2/3 results from the lead medication pemvidutide for MASH is a big boost. Interest from institutions rises, and the funding runway becomes longer.
2025 Target: $8
ALT stock forecast 2026
Pemvidutide is now in Phase 3, and a new pipeline asset is ready for Phase 1. Investors feel better about the company because of R&D success.
2026 Goal: $12
ALT stock forecast 2027
The first results from Phase 3 come in, and big pharmaceutical companies may be interested in licensing arrangements or strategic collaborations.
Goal for 2027: $20
ALT stock forecast 2028
We foresee a filing for Pemvidutide; a lower peak R&D investment means a lower burn rate. Payments connected to the first transaction start.
2028 Goal: $30
ALT stock forecast 2029
Regulatory clearance and upfront milestone payments make the value go up a lot.
2029 Goal: $45
ALT stock forecast 2030
Launch of treatment and early sales; ALT moves from the pipeline stage to the commercial stage, getting prescribers and payers on board.
Goal for 2030: $60
ALT stock forecast 2031
Adding new indications and income sources to repeated trial growth into obesity and metabolic comorbidities.
2031 Target: $80
ALT stock forecast 2032
Pemvidutide is being rolled out over the world, and fresh mid-stage candidates keep the pipeline going.
2032 Goal: $100
ALT stock forecast 2033
Sustainable market launch and follow-on indications create topline leverage and better profitability.
2033 Goal: $130
ALT stock forecast 2034
The next-gen pipeline is halfway done. Diversification makes risk/reward and value better.
2034 Target: $160
ALT stock forecast 2035
There are several signs that cash flows will stay stable. EPS goes up when R&D slows down and pricing power goes up.
2035 Target: $200
ALT stock forecast 2036
With sales of more than $1 billion, Pemvidutide becomes a blockbuster. The second product enters Phase 3.
2036 Goal: $250
ALT stock forecast 2037
The biotech industry is still growing as the firm moves to become a multi-product biopharma.
Goal for 2037: $300
ALT stock forecast 2038
New products in the pipeline; recurrent income helps keep the growth model going.
Goal for 2038: $350
ALT stock forecast 2039
Altimmune’s revenue grows by 20–25% per year and it makes a constant profit.
Goal for 2039: $400
ALT stock forecast 2040
Altimmune is a well-rounded biopharma firm that makes blockbuster medications, has good profitability, and does a lot of research and development.
Goal for 2040: $500
📈 Table of Yearly Price Targets
| Year | Price Target (USD) |
|---|---|
| 2025 | 8 |
| 2026 | 12 |
| 2027 | 20 |
| 2028 | 30 |
| 2029 | 45 |
| 2030 | 60 |
| 2031 | 80 |
| 2032 | 100 |
| 2033 | 130 |
| 2034 | 160 |
| 2035 | 200 |
| 2036 | 250 |
| 2037 | 300 |
| 2038 | 350 |
| 2039 | 400 |
| 2040 | 500 |
🚀 Main Reasons for Growth
- Pemvidutide clinical advancement: This is the key to unlocking value upside.
- Pipeline expansion with a wider range of metabolic first-pass candidates.
- Strategic alliances and licensing: Getting big pharmaceutical companies involved helps with both validation and financial flow.
- A strong financial sheet helps R&D and avoids dilution.
- Operational leverage when the product starts to be sold.
- Valuation multiple expansion as ALT starts making money and grows.
⚠️ Risks and Things to Think About
- High risk in clinical trials: failures might lead to big drops.
- Constantly burning cash before making money.
- Possible dilution from future investment rounds.
- Regulatory hurdles in price negotiations and getting things approved.
- Biotech volatility may be quite high around trial and regulatory news.
📝 Final Thoughts
If Altimmune keeps working on pemvidutide and other possibilities in its pipeline, it might become a successful drug business by 2035. But important clinical and regulatory milestones must be accomplished. Long-term predictions say that the price might go up to $500 by 2040, but investors should think carefully about the risks of execution and the biotech sector’s volatility.